Aptahem AB is a clinical stage biotechnology company based in Malmö, Sweden. They specialize in developing RNA-based pharmaceuticals known as aptamers, which are targeted towards treating life-threatening conditions involving coagulation, inflammation, and tissue damage. Aptahem aims to address the global medical need for therapies in sepsis and other acute inflammatory conditions.

Their lead candidate, Apta-1, is currently in the early clinical phase. In preclinical studies, Apta-1 has shown promising results as a treatment for sepsis and critical conditions associated with it, thanks to its anti-thrombotic, immunomodulating, and tissue repairing properties. Aptahem plans to build a diverse portfolio of aptamer-based treatments and develop their RNA-aptamer technology to fulfill long-term medical needs.

Their vision is to deliver top-quality RNA-based drugs for sepsis and severe inflammatory conditions, ultimately saving lives and improving treatment options. Aptahem's mission is to develop RNA-based drugs with a focus on demonstrating the potential benefits of Apta-1 in patients with sepsis and other severe inflammatory conditions. Aptahem follows a business strategy of taking drug candidates through the early development phase and seeking license or collaboration partners for late-stage development and market approval.

They implement a cost-effective competence strategy by recruiting experts in business management, pharmaceutical development, clinical trials, regulatory procedures, licensing, and patent applications. Since its establishment in 2014, Aptahem has achieved significant milestones in its journey to develop a unique treatment for severe inflammatory conditions like sepsis. For more information, you can reach out to Aptahem AB at their office on Norra Vallgatan 58, Malmö, Sweden.

You can also contact them via email at info@aptahem. com or find them on social media platforms like Facebook and LinkedIn